fa
Feedback

فریب کلاهبرداران را نخورید! تل‌متریو این کانال‌ها را شناسایی و برچسب‌گذاری می‌کند 👉 برای مشاهده برچسب، اشتراک تهیه کنید

JAMA (Journal of the American Medical Association)

JAMA (Journal of the American Medical Association)

رفتن به کانال در Telegram

All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot

نمایش بیشتر

📈 تحلیل کانال تلگرام JAMA (Journal of the American Medical Association)

کانال JAMA (Journal of the American Medical Association) (@jamaupdates) در بخش زبانی انگلیسی بازیگری فعال است. در حال حاضر جامعه شامل 17 069 مشترک است و جایگاه 1 455 را در دسته پزشکی و رتبه 2 173 را در منطقه الولايات المتحدة الأمريكية دارد.

📊 شاخص‌های مخاطب و پویایی

از زمان ایجاد در невідомо، پروژه رشد سریعی داشته و 17 069 مشترک جذب کرده است.

بر اساس آخرین داده‌ها در تاریخ 16 نوامبر, 2026، کانال فعالیت پایداری دارد. در ۳۰ روز گذشته تغییر اعضا برابر 371 و در ۲۴ ساعت گذشته برابر 13 بوده و همچنان دسترسی گسترده‌ای حفظ شده است.

  • وضعیت تأیید: تأیید نشده
  • نرخ تعامل (ER): میانگین تعامل مخاطب 4.24% است و در ۲۴ ساعت نخست پس از انتشار، محتوا معمولاً 1.89% واکنش نسبت به کل مشترکان کسب می‌کند.
  • دسترسی پست‌ها: هر پست به طور میانگین 723 بازدید دریافت می‌کند. در اولین روز معمولاً 323 بازدید جمع‌آوری می‌شود.
  • واکنش‌ها و تعامل: مخاطبان به‌طور فعال حمایت می‌کنند؛ میانگین واکنش به هر پست 1 است.
  • علایق موضوعی: محتوا بر موضوعات کلیدی مانند patient, disease, treatment, drug, guideline تمرکز دارد.

📝 توضیح و سیاست محتوایی

نویسنده این فضا را محل بیان دیدگاه‌های شخصی توصیف می‌کند:
“All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot”

به لطف به‌روزرسانی‌های پرتکرار (آخرین داده در تاریخ 17 نوامبر, 2026)، کانال همواره به‌روز و دارای دسترسی بالاست. تحلیل‌ها نشان می‌دهد مخاطبان به‌طور فعال با محتوا تعامل دارند و آن را به نقطه اثرگذاری مهم در دسته پزشکی تبدیل کرده‌اند.

17 069
مشترکین
+1324 ساعت
+967 روز
+37130 روز

در حال بارگذاری داده‌ها

جذب مشترکین
نوامبر '26
نوامبر '26
+283
در 1 کانال‌ها
اکتبر '26
+291
در 0 کانال‌ها
Get PRO
سپتامبر '26
+301
در 0 کانال‌ها
Get PRO
اوت '26
+361
در 0 کانال‌ها
Get PRO
ژوئیه '26
+440
در 0 کانال‌ها
Get PRO
ژوئن '26
+422
در 1 کانال‌ها
Get PRO
مه '26
+584
در 0 کانال‌ها
Get PRO
آوریل '26
+437
در 0 کانال‌ها
Get PRO
مارس '26
+217
در 0 کانال‌ها
Get PRO
فوریه '26
+247
در 0 کانال‌ها
Get PRO
ژانویه '26
+321
در 0 کانال‌ها
Get PRO
دسامبر '25
+277
در 0 کانال‌ها
Get PRO
نوامبر '25
+366
در 2 کانال‌ها
Get PRO
اکتبر '25
+164
در 0 کانال‌ها
Get PRO
سپتامبر '25
+12
در 0 کانال‌ها
Get PRO
اوت '25
+29
در 0 کانال‌ها
Get PRO
ژوئیه '25
+30
در 0 کانال‌ها
Get PRO
ژوئن '25
+17
در 0 کانال‌ها
Get PRO
مه '25
+9
در 0 کانال‌ها
Get PRO
آوریل '25
+5
در 0 کانال‌ها
Get PRO
مارس '25
+17
در 0 کانال‌ها
Get PRO
فوریه '25
+12
در 0 کانال‌ها
Get PRO
ژانویه '25
+18
در 1 کانال‌ها
Get PRO
دسامبر '24
+237
در 0 کانال‌ها
Get PRO
نوامبر '24
+1 122
در 0 کانال‌ها
Get PRO
اکتبر '24
+1 120
در 0 کانال‌ها
Get PRO
سپتامبر '24
+1 527
در 1 کانال‌ها
Get PRO
اوت '24
+1 128
در 1 کانال‌ها
Get PRO
ژوئیه '24
+1 216
در 0 کانال‌ها
Get PRO
ژوئن '24
+781
در 1 کانال‌ها
Get PRO
مه '24
+797
در 1 کانال‌ها
Get PRO
آوریل '24
+808
در 1 کانال‌ها
Get PRO
مارس '24
+821
در 2 کانال‌ها
Get PRO
فوریه '24
+753
در 1 کانال‌ها
Get PRO
ژانویه '24
+768
در 0 کانال‌ها
Get PRO
دسامبر '23
+716
در 1 کانال‌ها
Get PRO
نوامبر '23
+96
در 1 کانال‌ها
Get PRO
اکتبر '23
+86
در 0 کانال‌ها
Get PRO
سپتامبر '23
+73
در 0 کانال‌ها
Get PRO
اوت '23
+90
در 0 کانال‌ها
Get PRO
ژوئیه '23
+107
در 0 کانال‌ها
Get PRO
ژوئن '23
+105
در 0 کانال‌ها
Get PRO
مه '23
+169
در 0 کانال‌ها
Get PRO
آوریل '23
+128
در 0 کانال‌ها
Get PRO
مارس '23
+84
در 0 کانال‌ها
Get PRO
فوریه '23
+75
در 0 کانال‌ها
Get PRO
ژانویه '23
+71
در 0 کانال‌ها
Get PRO
دسامبر '22
+74
در 0 کانال‌ها
Get PRO
نوامبر '22
+149
در 0 کانال‌ها
Get PRO
اکتبر '22
+90
در 0 کانال‌ها
Get PRO
سپتامبر '22
+138
در 0 کانال‌ها
Get PRO
اوت '22
+77
در 0 کانال‌ها
Get PRO
ژوئیه '22
+50
در 0 کانال‌ها
Get PRO
ژوئن '22
+96
در 0 کانال‌ها
Get PRO
مه '22
+75
در 0 کانال‌ها
Get PRO
آوریل '22
+80
در 0 کانال‌ها
Get PRO
مارس '22
+65
در 0 کانال‌ها
Get PRO
فوریه '22
+26
در 0 کانال‌ها
Get PRO
ژانویه '22
+56
در 0 کانال‌ها
Get PRO
دسامبر '21
+44
در 0 کانال‌ها
Get PRO
نوامبر '21
+39
در 0 کانال‌ها
Get PRO
اکتبر '21
+61
در 0 کانال‌ها
Get PRO
سپتامبر '21
+66
در 0 کانال‌ها
Get PRO
اوت '21
+65
در 0 کانال‌ها
Get PRO
ژوئیه '21
+96
در 0 کانال‌ها
Get PRO
ژوئن '21
+120
در 0 کانال‌ها
Get PRO
مه '21
+130
در 0 کانال‌ها
Get PRO
آوریل '21
+812
در 0 کانال‌ها
تاریخ
رشد مشترکین
اشارات
کانال‌ها
17 نوامبر+1
16 نوامبر+14
15 نوامبر+19
14 نوامبر+10
13 نوامبر+15
12 نوامبر+5
11 نوامبر+17
10 نوامبر+21
09 نوامبر+4
08 نوامبر+12
07 نوامبر+23
06 نوامبر+2
05 نوامبر+17
04 نوامبر+17
03 نوامبر+22
02 نوامبر+76
01 نوامبر+8
پست‌های کانال
Blood Conservation and Choice in Surgical Transfusion https://jamanetwork.com/journals/jama/fullarticle/2856799 This Viewpoint discusses blood conservation and surgical transfusion, including patient blood management and bloodless medicine and surgery, among patients who refuse blood.

2
Alcohol Consumption During Pregnancy in the US—Reply https://jamanetwork.com/journals/jama/fullarticle/2856800 In Reply We thank Dr Fan and colleagues for their thoughtful letter and for engaging with our study, which reported an increasing trend in alcohol consumption during pregnancy in the US over the past 2 decades. As discussed by the authors, our descriptive results indicate that older maternal age and tobacco use were both notable correlates of any alcohol use, raising questions about overlapping exposure patterns and potential synergistic effects. While our study was designed to assess population-level trends and does not address etiologic aims directly, we are encouraged that the findings have raised other substantive research questions that could have important implications for prevention and practice.
248
3
Alcohol Consumption During Pregnancy in the US https://jamanetwork.com/journals/jama/fullarticle/2856801 To the Editor The Research Letter by Dr Bruzelius and colleagues documents increased prevalence of alcohol use among pregnant women in the US from 2011 to 2024, particularly among those with older maternal age (35-49 years; 18.2%) and tobacco use (26.3%). Among pregnant women reporting any alcohol use, 68.1% of those who used tobacco also reported binge or heavy drinking, compared with 31.3% of people who did not use tobacco, suggesting a particularly high-risk subgroup that warrants further investigation.
207
4
GLP-1 Utilization After Withdrawal of Medicaid Coverage for Weight Loss https://jamanetwork.com/journals/jama/fullarticle/2856802 This cross-sectional study uses data from Medicaid State Drug Utilization Data to examine associations of coverage withdrawal with Medicaid beneficiaries’ utilization of weight loss–approved glucagon-like peptide-1s.
163
5
Absolute Risk of Progression to Cognitive Impairment Based on Plasma p-Tau217, Age, Sex, and APOE ε4 https://jamanetwork.com/journals/jamaneurology/fullarticle/2856722 This cohort study examines data from the Mayo Clinic Study of Aging and Alzheimer’s Disease Neuroimaging Initiative to determine the 5- and 10-year absolute risks of mild cognitive impairment and dementia among individuals who are biomarker positive and cognitively unimpaired.
174
6
Agent Orange Exposure and Parkinson Disease Among US Veterans https://jamanetwork.com/journals/jamaneurology/fullarticle/2856723 This cohort study investigates the association between Agent Orange and risk of incident Parkinson disease diagnosis among US veterans.
167
7
Nationwide Geographic Access to Subcutaneous Anti-Amyloid Alzheimer Disease Therapy Infrastructure https://jamanetwork.com/journals/jamaneurology/fullarticle/2856724 This cross-sectional study describes how geographic availability of the minimum health care infrastructure required for subcutaneous therapy for Alzheimer disease treatment varies by age and location across the US.
169
8
Intraocular Hemorrhage After Digital Subtraction Myelography https://jamanetwork.com/journals/jamaneurology/fullarticle/2856725 This case report describes a young adult patient with intraretinal hemorrhages in both eyes resulting in reduction of visual acuity in the left eye.
155
9
Agent Orange and Parkinson Disease—The War Ended, the Exposure Did Not https://jamanetwork.com/journals/jamaneurology/fullarticle/2856726 Agent Orange was a defoliant widely used by the US during the Vietnam War to uncover the positions of North Vietnamese soldiers. The weed killer was a 50:50 mixture of the herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) along with small amounts of a potent carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a by-product of the manufacturing process. From 1962 to 1971, the US sprayed at least 75 million liters (20 million gallons) of defoliants over Vietnam and more over Cambodia, Laos, Thailand, South Korea, and possibly Guam, Panama, and even around military bases in the US.
160
10
HEPA Filtration in Care Homes—Distinguishing Implementation From Intervention Failure https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856318 To the Editor Hay et al should be commended for conducting one of the first large pragmatic trials addressing an important and clinically relevant infection-prevention strategy in a highly vulnerable population. However, I believe that several aspects of this study warrant further consideration.
230
11
Evaluation of Identified Serious Risks for Drugs and Biologics Using Surveillance Systems https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856319 This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.
252
12
Value Judgments in Comparing Dialysis Facility Performance https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856321 In 2025, the Centers for Medicare & Medicaid Services (CMS) stopped collecting information about race and ethnicity in the dialysis quality measurement system. Koukounas and colleagues in this issue of JAMA Internal Medicine consider how this change might impact comparisons among dialysis facilities. Using national data, they estimated standardized mortality ratios (SMRs) for these facilities, contrasting the results from risk-adjustment models that either include or exclude race and ethnicity. They find that dialysis facilities that serve more socially disadvantaged patients have better SMRs when the model does not adjust for race and ethnicity.
272
13
Pediatric Obesity Pharmacotherapy https://jamanetwork.com/journals/jama/fullarticle/2856798 In the current issue of JAMA, Dr Kelly and colleagues present results from SURMOUNT-ADOLESCENTS, a clinical trial of tirzepatide among adolescents with obesity. The results are impressive: mean body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) decreased by 18.5% with tirzepatide compared with a 0.5% increase with placebo, a treatment difference of 19 percentage points at 72 weeks. Nearly half of tirzepatide-treated participants achieved a BMI reduction of at least 20%, and 53.5% of tirzepatide-treated participants achieved a BMI below the 95th percentile at week 72, compared with 7.1% receiving placebo. As evidence supporting antiobesity medications continues to mount, the question is increasingly not whether pharmacotherapy has a role in pediatric obesity treatment, but which medications should be used for which patients and under what circumstances.
425
14
FDA Approves Novel Treatment for Chronic Hepatitis B https://jamanetwork.com/journals/jama/fullarticle/2856883 The US Food and Drug Administration (FDA) approved bepirovirsen, marketed as Hibsago, in combination with existing antiviral therapy for adults without cirrhosis who have chronic hepatitis B virus (HBV) infection.
753
15
Updated Guidance Released for Type 2 Diabetes Care https://jamanetwork.com/journals/jama/fullarticle/2856884 The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) released a joint consensus statement offering updated clinical guidance for type 2 diabetes.
716
16
Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence Risk https://jamanetwork.com/journals/jama/fullarticle/2856885 A personalized messenger RNA (mRNA) cancer vaccine significantly lowered the risk of disease recurrence or death in patients with high-risk melanoma, a phase 3 trial found.
708
17
Why Do COVID-19 Shots Trigger a Fever for Some? https://jamanetwork.com/journals/jama/fullarticle/2856877 This Medical News article discusses a study that linked the gut microbiome to fever after COVID-19 vaccination.
660
18
Salt Substitutes Come to the Table https://jamanetwork.com/journals/jama/fullarticle/2856876 This Medical News article discusses efforts to increase the use of potassium-enriched salt substitutes to lower sodium intake and prevent and manage hypertension.
601
19
JAMA Editors' Summary Podcast November 13, 2026 https://jamanetwork.com/journals/jama/fullarticle/2856887 Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
570
20
US Health Insurance Coverage Declines https://jamanetwork.com/journals/jama/fullarticle/2856886 US health insurance coverage and access are in decline after 15 years of expansion, according to a 2026 survey from the Commonwealth Fund.
538